WILLIAM PEACOCK to Factor Xa Inhibitors
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Factor Xa Inhibitors.
Connection Strength
3.689
-
Comparison of the Incidence of Major Bleeding With Rivaroxaban Use Among Nonvalvular Atrial Fibrillation Patients With Versus Without Diabetes Mellitus. Am J Cardiol. 2017 Mar 01; 119(5):753-759.
Score: 0.554
-
CHA2DS2-VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Ann Emerg Med. 2017 May; 69(5):541-550.e1.
Score: 0.553
-
Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design. Acad Emerg Med. 2016 11; 23(11):1280-1286.
Score: 0.550
-
Risk Factors for Major Bleeding in Rivaroxaban Users With Atrial Fibrillation. J Am Coll Cardiol. 2016 09 06; 68(10):1144-6.
Score: 0.544
-
Target-specific Oral Anticoagulants in the Emergency Department. J Emerg Med. 2016 Feb; 50(2):246-57.
Score: 0.515
-
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. Stroke. 2020 07; 51(7):2139-2147.
Score: 0.177
-
The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Am J Emerg Med. 2020 06; 38(6):1163-1170.
Score: 0.171
-
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med. 2018 Jun 07; 378(23):2191-2201.
Score: 0.153
-
Doses of apixaban and rivaroxaban prescribed in real-world United States cardiology practices compared to registration trials. Curr Med Res Opin. 2016 07; 32(7):1277-9.
Score: 0.132
-
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers. Hosp Pract (1995). 2014 Oct; 42(4):75-82.
Score: 0.119
-
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. Stroke. 2020 08; 51(8):2386-2394.
Score: 0.044
-
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. J Stroke Cerebrovasc Dis. 2018 Jun; 27(6):1673-1682.
Score: 0.038
-
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 2017 08; 48(8):2142-2149.
Score: 0.036
-
Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice. Heart Lung Circ. 2018 Mar; 27(3):390-393.
Score: 0.036
-
Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism. Pharmacotherapy. 2016 10; 36(10):1109-1115.
Score: 0.034
-
Outcomes associated with observation status versus inpatient management of pulmonary embolism patients anticoagulated with rivaroxaban. Int J Cardiol. 2016 Nov 01; 222:846-849.
Score: 0.034